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HDAC inhibitorFriedreich ataxia (FRDA) is an inherited neurodegenerative disorder caused by GAA repeat expansion within
the FXN gene, leading to epigenetic changes and heterochromatin-mediated gene silencing that result in a
frataxin protein deﬁcit. Histone deacetylase (HDAC) inhibitors, including pimelic o-aminobenzamide
compounds 106, 109 and 136, have previously been shown to reverse FXN gene silencing in short-term
studies of FRDA patient cells and a knock-in mouse model, but the functional consequences of such
therapeutic intervention have thus far not been described. We have now investigated the long-term
therapeutic effects of 106, 109 and 136 in our GAA repeat expansion mutation-containing YG8R FRDA mouse
model. We show that there is no overt toxicity up to 5 months of treatment and there is amelioration of the
FRDA-like disease phenotype. Thus, while the neurological deﬁcits of this model are mild, 109 and 106 both
produced an improvement of motor coordination, whereas 109 and 136 produced increased locomotor
activity. All three compounds increased global histone H3 and H4 acetylation of brain tissue, but only 109
signiﬁcantly increased acetylation of speciﬁc histone residues at the FXN locus. Effects on FXN mRNA
expression in CNS tissues were modest, but 109 signiﬁcantly increased frataxin protein expression in brain
tissue. 109 also produced signiﬁcant increases in brain aconitase enzyme activity, together with reduction of
neuronal pathology of the dorsal root ganglia (DRG). Overall, these results support further assessment of
HDAC inhibitors for treatment of Friedreich ataxia.).
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Friedreich ataxia (FRDA) is an autosomal recessive neurodegen-
erative disorder predominantly caused by a homozygous GAA repeat
expansion mutation within intron 1 of the FXN gene (Campuzano
et al., 1996). Normal individuals have 5–30 GAA repeat sequences,
whereas affected individuals have from approximately 70 to more
than 1000 GAA triplets. The effect of the GAA expansionmutation is to
reduce the production of frataxin (Campuzano et al., 1997), a
ubiquitously expressed mitochondrial protein that acts in iron–sulfur
cluster and heme biosynthesis (Pandolfo and Pastore, 2009). Frataxin
insufﬁciency leads to decreased activity of iron–sulfur cluster
enzymes, such as aconitase and the mitochondrial respiratory chain
complexes (Bradley et al., 2000), followed by mitochondrial iron
accumulation and resultant cell death, with the primary sites ofpathology being the large sensory neurons of the DRG and the dentate
nucleus of the cerebellum (Koeppen et al., 2007; Koeppen et al.,
2009). The outcome is progressive spinocerebellar neurodegenera-
tion, causing symptoms of incoordination (“ataxia”), muscle weak-
ness and sensory loss. There is also pathology of non-neuronal tissues,
with cardiomyopathy a common secondary effect and diabetes found
in 10% of FRDA patients (Schulz et al., 2009). Affected individuals are
conﬁned to a wheelchair within 20 years after the ﬁrst appearance of
symptoms, and most commonly die in early adulthood from the
associated heart disease. Therefore, there is urgent need to develop an
effective therapy for this lethal disorder.
Thus far, FRDA clinical trials using antioxidants and iron chelators
have demonstrated some limited success at ameliorating secondary
disease effects (Schulz et al., 2009). However, amore effective therapy
may be achieved by targeting the more immediate effects of the
GAA repeat expansion mutation to elevate deﬁcient frataxin levels.
Although the mechanisms by which the GAA repeat expansion leads
to a frataxin deﬁcit are currently not known, two non-exclusive
hypotheses have been put forward. Firstly, it has been suggested that
the GAA repeat expansion may adopt abnormal non-B DNA or
DNA•RNA hybrid triplex structures that interfere with FXN gene
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evidence that GAA repeat expansions can produce a heterochromatin-
mediated gene silencing effect (Saveliev et al., 2003), likely acting
through epigenetic processes, such as DNA methylation and histone
modiﬁcations. In support of this second hypothesis, recent studies of
FRDA patient cells and tissues by ourselves and others have identiﬁed
several GAA expansion-speciﬁc epigenetic changes (Al-Mahdawi
et al., 2008; De Biase et al., 2009; Greene et al., 2007; Herman et al.,
2006). Thus, GAA repeat expansions are associated with (i) increased
DNA methylation in the region of FXN intron 1 immediately upstream
of the GAA repeat (Al-Mahdawi et al., 2008; Greene et al., 2007);
(ii) reduced H3K9 acetylation and increased H3K9 and H3K27
trimethylation at the FXN promoter (Al-Mahdawi et al., 2008; De
Biase et al., 2009), and (iii) reduced acetylation of several H3 and H4
lysine residues together with increased H3K9 di- and trimethylation
in both the upstream and downstream GAA regions (Al-Mahdawi
et al., 2008; Greene et al., 2007; Herman et al., 2006). Therefore, there
is ample evidence to propose reversal of FXN gene silencing by the use
of epigenetic-modifying compounds as a potential therapy for FRDA.
HDAC inhibitors are a structurally diverse group of compounds
that have beenwidely used in the treatment of various human cancers
(Cang et al., 2009; Monneret, 2005; Prince et al., 2009). They are
generally believed to act by increasing global histone acetylation and
thereby reactivating epigenetically silenced genes, although HDAC
inhibitors can also promote acetylation of non-histone proteins
(Butler and Bates, 2006). Initial treatment of FRDA lymphoblastoid
cells using a panel of commercially available HDAC inhibitors revealed
that only the benzamide compound BML-210 (N1-(2-aminophenyl)-
N8-phenyloctanediamide) produced a signiﬁcant increase of FXN
mRNA expression (Herman et al., 2006). Subsequent synthesis of
analogs of BML-210 identiﬁed a pimelic o-aminobenzamide com-
pound, 4b (N1-(2-aminophenyl)-N7-phenylheptanediamide), which
was shown to act on FRDA primary lymphocytes to signiﬁcantly
increase acetylation of H3K14, H4K5 and H4K12 in the FXN upstream
GAA region and to increase FXN mRNA levels by 2.5-fold (Herman
et al., 2006). Further development of this family of benzamide HDAC
inhibitors identiﬁed three other pimelic o-aminobenzamide com-
pounds, 106 (N1-(2-aminophenyl)-N7-p-tolylheptanediamide), 136
(N-(6-(2-amino-4-ﬂuorophenylamino)-6-oxyhexyl)-4-methylbenza-
mide) and 109 (N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methyl-
benzamide), which have each undergone investigations to determine
pharmacokinetic properties, safety and efﬁcacy in short-term treat-
ments of FRDA patient cells and mice (Chou et al., 2008; Rai et al.,
2010, 2008; Soragni et al., 2008; Xu et al., 2009). 106, 136 and 109 all
act as slow-on, slow-off, tight binding inhibitors of class I HDACs, with
a preference for HDAC3 (Chou et al., 2008; Rai et al., 2010; Xu et al.,
2009). Furthermore, they all produce signiﬁcant short-term increases
in H4K5 acetylation and FXNmRNA and frataxin protein expression in
FRDA primary lymphocytes and brain and heart tissues of FRDA KIKI
mice (Rai et al., 2010, 2008).
We have established a GAA repeat expansion mutation-based
mouse model of FRDA, designated YG8R, by cross breeding YG8
human genomic YAC transgenic mice that contain the entire FXN
gene and expanded GAA repeats (Al-Mahdawi et al., 2004) with
heterozygous Fxn knockout mice (Cossee et al., 2000). The
resulting YG8R mice rescue the embryonic lethality of the Fxn
homozygous knockout alleles by expressing only human frataxin
from the GAA repeat-mutated FXN transgene in a mouse frataxin
null background (Al-Mahdawi et al., 2006). The YG8R mice exhibit
an FRDA-like molecular disease phenotype that includes intergen-
erational and somatic instability of the GAA repeat expansion
mutation (Al-Mahdawi et al., 2004; Clark et al., 2007), together
with increased DNA methylation, reduced histone H3 and H4
acetylation and increased di- and trimethylated H3K9 at the FXN
upstream GAA region, when compared with Y47R control trans-
genic mice that contain the same human FXN YAC transgene butwith normal-sized GAA repeats (Al-Mahdawi et al., 2008). Further-
more, YG8R frataxin mRNA levels in brain tissue are reduced to
approximately 30% when compared with Y47R control transgenic
mice (Al-Mahdawi et al., 2008). Although the YG8R mice do not
show reduction of frataxin mRNA levels in brain tissue when
compared with wild-type mice, frataxin protein levels are reduced
to approximately 70% that of wild-type mice (Al-Mahdawi et al.,
2006). YG8R mice are also likely to have impaired function of the
human transgene-derived frataxin, resulting in deﬁcits that are
consistent with FRDA disease, including mildly impaired motor
coordination ability, reduced aconitase enzyme activity and
abnormal DRG neuronal pathology (Al-Mahdawi et al., 2006).
Therefore, we consider YG8R to be a suitable mouse model in which
to investigate potential FRDA therapies and we now report the
effects of prolonged treatment with HDAC inhibitors 106, 136 and
109. Our results show that each compound is well tolerated during
chronic subcutaneous dosing for up to 5 months. We detect
improvements of behavioral, molecular, biochemical and histolog-
ical measurements, particularly with 109, that are consistent with
the compounds crossing the blood-brain barrier to ameliorate
FRDA-like disease effects.
Materials and methods
Animal procedures
Genotyping of mice to identify human transgenic GAA sequences
and endogenous mouse Fxn knockout alleles was performed as
previously described (Pook et al., 2001). Mice were housed in
conventional open cages with Litaspen Premium 8/20 bedding,
paper wool nesting and standard fun tunnel environmental enrich-
ment, with 13 h light, 11 h dark, 20-23 °C and 45–60% humidity. The
mice were given a diet of SDS RM3 Expanded food pellets and
standard drinking water. All procedures were carried out in
accordance with the UK Home Ofﬁce ‘Animals (Scientiﬁc Procedures)
Act 1986.’
Drug treatment
HDAC inhibitors 106 (N1-(2-aminophenyl)-N7-p-tolylheptanedia-
mide), 136 (N-(6-(2-amino-4-ﬂuorophenylamino)-6-oxyhexyl)-4-
methylbenzamide) and 109 (N-(6-(2-aminophenylamino)-6-oxy-
hexyl)-4-methylbenzamide) were obtained from Repligen Corpora-
tion, Waltham, MA, USA, and were synthesized as previously
described (Rai et al., 2010, 2008). 30 mg/ml 106 was prepared in a
vehicle solution of 2.5% DMSO, 40% hydroxypropyl-β-cyclodextrin,
140 mM Na acetate pH5.2, and 10 mg/ml 136 and 109 were prepared
in a vehicle solution of 20% glycerol, 20% PEG400, 20% propylene
glycol, 5 mM Na acetate pH 5.2. Mice were given subcutaneous
injections of 150 mg/kg 106 three times per week for 4.5 months, or
50 mg/kg 136 or 100 mg/kg 109 ﬁve times per week for 5 months,
followed by culling for tissue collection 24 h after the ﬁnal injection.
Behavioral assessments
Rotarod performances of YG8R and C57BL/6J wild-type mice were
assessed using a Ugo Basile 7650 accelerating rotarod treadmill and
open ﬁeld locomotor activity was assessed using a gridded perspex
box in light room conditions, as previously described (Al-Mahdawi
et al., 2006). Ambulatory distance and vertical counts were measured
over 2 min periods in the dark and repeated four times for eachmouse
using a beam-breaker activity monitor (Medical Devices, Inc.). For
ﬁnal analysis, the fold change in mean performance time for each
group of mice was calculated and compared with the original mean
performance time.
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Total RNA was isolated from snap frozen tissues by homogeniza-
tion with Trizol (Invitrogen) and cDNA was then prepared by using
AMV reverse transcriptase (Invitrogen) with oligo-dT primers. Levels
of human transgenic FXN or endogenous Fxn mRNA expression were
assessed by quantitative RT-PCR using an ABI7900 sequencer and
SYBR® Green (Applied Biosystems) with the following primers that
equally amplify human and mouse sequences: FRT-I 5'-TTGAA-
GACCTTGCAGACAAG-3' and RRT-II 5'-AGCCAGATTTGCTTGTTTGG-3'.
Mouse Gapdh RT-PCR primers used for normalization were as follows:
GapdhmF 5'-ACCCAGAAGACTGTGGATGG-3' and GapdhmR 5'-
GGATGCAGGGATGATGTTCT-3'.
Gapdh mRNA expression was similarly quantiﬁed using GapdhmF
and GapdhmR primers and using mouse Rer1 RT-PCR primers for
normalization, as follows: RER1-F: 5'-CCACCTAAACCTTTTCATTGCG-3'
and RER1-R: 5'-TTTGTAGCTGCGTGCCAAAAT-3'.
Reactions were carried out in triplicate for each biological sample
(n=4).Western blot analysis
Protein lysates were obtained from snap frozen brain tissues, and
frataxinWestern blot analysis was carried out as previously described
(Pook et al., 2001), using an anti-frataxin rabbit polyclonal antibody
(Santa Cruz 25820). Histone H3 and H4 acetylation levels were
determined by Western blot analysis using anti-acetyl-Histone H3
(Upstate 06-599) and anti-acetyl-Histone H4 (Upstate 06-866)
antibodies, respectively. In all cases, normalization was carried out
using a rat anti-α-tubulin monoclonal antibody (Abcam AB6160).
Densitometry was carried out using UN-SCAN-IT software (Silk
Scientiﬁc Corporation) and in all cases (n=4).ChIP analysis
ChIP analysis was carried out by initial cross-linking of DNA and
protein by formaldehyde treatment of homogenized frozen tissue
samples. DNA was then sheared by sonication, followed by immuno-
precipitation with commercially available anti-acetylated histone H3
and H4 antibodies: H3K9ac, H4K5ac, and H4K12ac (Upstate). For each
experiment, normal rabbit serum (SIGMA) was used as a minus
antibody immunoprecipitation control. After reversal of cross-linking,
quantitative PCR ampliﬁcation of the resultant co-immunoprecipi-
tated DNA was carried out with SYBR® Green in an ABI7900
sequencer (Applied Biosystems) using three sets of FXN primers
(Pro, Up and Down) and mouse Gapdh primers, as previously
described (Al-Mahdawi et al., 2008; Herman et al., 2006). Each tissue
sample was subjected to two independent ChIP procedures, followed
by triplicate quantitative PCR analysis.Aconitase activity assay
Aconitase activities were determined by homogenization of mouse
brain tissues on ice at 10% w/v in CellLytic MT Mammalian Tissue
Lysis/Extraction buffer (SIGMA, C3228), followed by centrifugation at
800×g for 10 min at 4 °C. Tissue lysates (50 μl) were then added to
200 μl of substrate mix (50 mM Tris/HCl pH 7.4, 0.4 mM NADP, 5 mM
Na citrate, 0.6 mM MgCl2, 0.1% (v/v) Triton X-100 and 1U isocitrate
dehydrogenase) and the reactions were incubated at 37 °C for 15 min,
followed by spectrophotometric absorbance measurements every
minute for 15 min at 340 nm 37 °C to determine the reaction slope.
Aconitase activities of mouse brain tissues were then normalized to
citrate synthase activities, which were determined using a citrate
synthase assay kit (SIGMA, CS0720).DRG histology
Histological preparations of mouse DRG were carried out by
dissection of paraformaldehyde-ﬁxed intact lumbar vertebrae, fol-
lowed by decalciﬁcation treatment in Hillman and Lee's EDTA daily for
5 days. Tissues were then embedded in parafﬁn wax, sectioned by
standard methods, deparafﬁnized with IMS and Histoclear (National
Diagnostics) and slides were stained with hematoxylin and eosin.
Statistical analysis
Body weight, rotarod performance, locomotor activity, ambulatory
distance and vertical counts beam-breaker data were analyzed by
two-way ANOVA for genotype (YG8R or wild-type) and time (age of
mice) to detect disease-like effects and for treatment (HDAC inhibitor
or vehicle) and time (age of mice) to detect drug effects. All other data
were analyzed by the Student's t test, with a signiﬁcance value set at
pb0.05.
Results
HDAC inhibitors 106, 136 and 109 are well tolerated in chronic dosing of
mice
HDAC inhibitors 106, 136 and 109 have previously been adminis-
tered subcutaneously to a separate GAA knock-in mouse model (KIKI
mice, where GAA repeats have been introduced into the mouse
frataxin gene) daily for a period of 3 days, without any toxic effects
(Rai et al., 2010, 2008). We wanted to determine if this lack of acute
toxicity could be maintained throughout long-term dosing regimes.
We initially treated one group of ﬁfteen 3- to 4-month-old YG8Rmice
with 150 mg/kg 106 by subcutaneous injection 3 times per week for a
period of 4.5 months, together with an age- and sex-matched YG8R
control group treated with vehicle only. We subsequently treated
three groups of 20 age- and sex-matched 3- to 4-month-oldYG8Rmice
with either 50 mg/kg 136, 100 mg/kg 109 or vehicle-only by
subcutaneous injection ﬁve times per week for a period of 5 months.
At the same time, we similarly treated three groups of 10 age-and sex-
matched 3- to 4-month-old wild-type (C57BL/6 J) mice (YG8R mice
are in a C57BL/6 J genetic background and Y47R control transgenic
mice were not available for this study) with either 50 mg/kg 136,
100 mg/kg 109 or vehicle-only by subcutaneous injection ﬁve times
per week for a period of 5 months.
The long-term administrations of 106, 136 and 109 were well
tolerated and no toxicity was generally observed in the mice
throughout the entire period of study. However, one 136-treated
YG8R mouse died from an unknown cause after 4 months and one
109-treated wild-type mouse showed a failure to thrive after
2 months and was therefore culled. Analysis of body weight over
time by two-way ANOVA detected a non-signiﬁcant (F=2.9,
p=0.086) reduction in the weight gain of YG8R mice compared
with wild-type mice. This mild detrimental phenotype remained
unaffected by prolonged treatment with 109 (F=1.28, p=0.25), but
treatment with 106 and 136 resulted in signiﬁcant further reductions
in weight gain (F=13.5, pb0.001 and F=5.0, pb0.05, respectively)
(Fig. S1), indicating that 109 is the best tolerated of the three
compounds under the dosing conditions tested.
106 and 109 improve motor coordination of YG8R FRDA mice
Motor coordination was assessed by change in performance on a
rotarod treadmill at monthly time points throughout the treatment
periods. An initial comparison of vehicle-treated YG8R and wild-type
mice revealed a gender-speciﬁc phenotype, which has not previously
been investigated or reported. Thus, no signiﬁcant difference in
rotarod performance was noted when both male and female values
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alone (Fig. 1B). However, analysis of female values alone revealed a
signiﬁcantly reduced rotarod performance (F=35.9, pb0.001) in
YG8Rmice (Fig. 1C).With this inmind, only the rotarod performances
of female mice were taken into account when determining any effect
of the HDAC inhibitors on motor coordination. Both 106 and 109
treatments were found to improve the rotarod performances of YG8R
female mice (F=44.2, pb0.001 and F=20.0, pb0.001, respectively)
(Fig. 1D and Fig. S1D), while 136 treatment showed no effect.
Furthermore, the rotarod improvement achieved by 109 treatment
appeared to be speciﬁc for YG8R mice, since no effect was seen with
109 treatment of wild-type female mice (Fig. 1D).
136 and 109 improve locomotor activity of YG8R FRDA mice
Several parameters were used to measure locomotor activity of
mice. However, unlike the analysis of motor coordination, no gender-
speciﬁc YG8R phenotype was observed and therefore the combined
male and female data are presented. Firstly, the open ﬁeld activity of
106- and 136-treated YG8R mice compared with vehicle-treated
YG8R mice was assessed by determining the distance moved within a
gridded perspex box under normal light conditions, as previously
described (Al-Mahdawi et al., 2006). 106 treatment had no effect on
activity, whereas 136 treatment signiﬁcantly increased activity in
YG8R mice (F=17.7, pb0.001) (Fig. S1E). Secondly, for the study of
136- and 109-treated YG8R and wild-type mice, beam-breaker
activity monitor apparatus was used to measure (i) the total
horizontal distance moved (‘ambulatory distance’) and (ii) a count
of the vertical movements due to rearing on hind limbs (‘vertical
counts’) within a 2-min period under dark conditions. Initial analysis
by two-way ANOVA detected a signiﬁcant ambulatory distance
disease-like phenotype of YG8R mice compared with wild-type
mice (F=6.0, pb0.05). Subsequent treatments with 136 and 109
both produced signiﬁcant increases in the ambulatory distance of
YG8R mice towards wild-type values (F=13.6, pb0.001 and F=22.3,
pb0.001, respectively) (Fig. 2A and B). These increases were speciﬁc
for YG8R mice, since 136 produced a non-signiﬁcant decrease
(F=0.34, p=0.56), while 109 produced a non-signiﬁcant increase
(F=1.92, p=0.167), in the ambulatory distance of wild-type miceFig. 1.Motor coordination analysis. Relative rotarod performances are shown for vehicle-treate
time period. (A) Combined male and female values (YG8R n=20, WT n=10), (B) male value
shown. (D) Values for 109-treated YG8R FRDA mice (purple) and wild-type (WT) mice (gree
represent s.e.m.(Fig. 2A and B). Two-way ANOVA analysis also detected a signiﬁcant
vertical counts disease-like phenotype of YG8R mice compared with
wild-type mice (F=24.5, pb0.001). Only 136 treatment caused a
signiﬁcant increase in the vertical counts of YG8R mice compared to
vehicle-treated controls (F=67.4, pb0.001) (Fig. 2C), and this effect
was speciﬁc for YG8R, because the values were signiﬁcantly decreased
in 136-treated wild-type mice (F=8.6, pb0.01). 109 treatment was
shown to have no effect (F=1.7, p=0.19) (Fig. 2D).
106, 136 and 109 increase general histone acetylation levels in the brain
To examine the effects of prolonged dosing of 106, 136 and 109 on
general histone acetylation within the brain tissue of YG8R and wild-
typemice, acetylated H3 and acetylated H4 levels were determined by
Western blotting analysis (Fig. 3). No differences in either acetylated
H3 or acetylated H4 levels were detected between wild-type and
YG8R mice. However, increases in both acetylated H3 and acetylated
H4 levels were detected in YG8R mice treated with all three HDAC
inhibitors compared to vehicle-treated controls, and similar increases
were seen in HDAC inhibitor-treated wild-type mice. Compound 109
exhibited a more pronounced effect on acetylated H3 levels, which
were increased by 1.5-fold, although not to statistical signiﬁcance
(Fig. 3C). In contrast, 106 and 136 had more prominent effects on
acetylated H4 levels, each producing signiﬁcant 1.4-fold increases
(pb0.05 and pb0.01, respectively) (Fig. 3D).
109 increases acetylated H3K9, H4K5 and H4K12 within the FXN
transgene and the endogenous mouse gapdh gene in YG8R brain tissue
We have previously detected comparatively reduced levels of
acetylated H3 and H4 histone residues in brain tissue of expanded
GAA repeat YG8 transgenic mice compared with normal-sized GAA
repeat Y47 transgenic mice by performing chromatin immunopre-
cipitation (ChIP) analysis at three regions of the FXN gene: the
promoter, upstream of the GAA repeat and downstream of the GAA
repeat (Al-Mahdawi et al., 2008). Therefore, to investigate HDAC
inhibitor effects after prolonged treatment of YG8R mice, we
performed ChIP analysis of acetylated H3K9, H4K5 and H4K12
residues at the same three FXN regions, comparing results fromd YG8R FRDAmice (red) and wild-type (WT)mice (blue) as fold-changes over a 5-month
s only (YG8R n=10, WT n=5), and (C) female values only (YG8R n=10, WT n=5) are
n) are shown together with vehicle-treated groups (YG8R n=10, WT n=5). Error bars
Fig. 2. Beam-breaker behavior analysis. Relative ambulatory distance (A, B) and vertical counts (C, D) are shown as fold-changes for vehicle-treated groups of YG8R FRDAmice (red)
and wild-type (WT) mice (blue) over a 5-month time period. (A) and (C) show 136-treated YG8R FRDA mice (purple) and wild-type (WT) mice (green). (B) and (D) show 109-
treated YG8R FRDA mice (purple) and wild-type (WT) mice (green). (YG8R n=20, WT n=10). Error bars represent s.e.m.
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tissues. We chose to examine H3K9 and H4K12 because these
residues previously showed the greatest decreases in acetylation in
YG8 transgenic mice, and H4K5 was chosen because this residue is
known to be themost preferentially modiﬁed by HDAC3, the principle
HDAC target of the pimelic o-aminobenzamide HDAC inhibitors (Chou
et al., 2008; Xu et al., 2009). Treatment with 106 produced little effect,Fig. 3. General H3 and H4 acetylation levels in YG8R brain tissues. Western blots showing (
(v)-, 136- and 109-treated YG8R mouse brain samples, together with α-tubulin controls.
(D) are shown for vehicle-treatedwild-type (WT)mice, and vehicle-, 106-, 136- and 109-tr
mouse value. In all cases, n=4 and error bars represent s.e.m. *pb0.05, **pb0.01.although non-signiﬁcant 1.6-fold and 2.3-fold increases of acetylated
H4K5 were observed in the FXN promoter and downstream GAA
regions, respectively (Fig. 4A–C). Similarly, treatment with 136
showed no effect (Fig. 4D–F). However, 109 treatment produced
striking increases in each of the three acetylated H3K9, H4K5 and
H4K12 residues in all three regions of the FXN locus, with the most
statistically signiﬁcant increases found at H3K9 and H4K5 residues.A) acetylated H3 histones (H3ac) and (B) acetylated H4 histones (H4ac) from vehicle
Densitometry calculations of acetylated H3 histones (C) and acetylated H4 histones
eated YG8Rmouse brain samples. Values are shown relative to the vehicle-treatedWT
Fig. 4. ChIP analysis of acetylated H3K9, H4K5 and H4K12 residues within the FXN locus of HDAC inhibitor- and vehicle-treated YG8R brain tissues. ChIP quantitative PCR results for
H3K9ac, H4K5ac and H4K12ac residues within the transgenic FXN promoter (A, D, G), upstream GAA region (B, E, H) and downstream GAA region (C, F, I) of mouse brain tissue are
represented as relative recovery (%), which was calculated as the amount of immunoprecipitated DNA compared to input DNA, subtracting the –Ab background value. The effects of
treatment with 106 (A–C, dark blue), 136 (D–F, red) and 109 (G–I, green) are shown in comparison to vehicle-treatments (light blue). n=3–6 and error bars represent s.e.m.
*pb0.05, **pb0.01, ***pb0.001.
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acetylated H3K9 residue, with 6-fold, 8-fold and 4.5-fold increases at
the promoter, upstream GAA and downstream GAA regions, respec-
tively (Fig. 4G–I). However, the most statistically signiﬁcant increases
were observed for the acetylated H4K5 residue at the promoter and
upstream GAA regions (Fig. 4G and H). At the same time, as a control
experiment, we investigated 109 effects on acetylation of H3K9, H4K5
and H4K12 in the endogenous mouse Gapdh gene, using the same
mouse brain tissues. As with the FXN gene, 109 produced increases in
all three acetylated histone residues, with signiﬁcant 8-fold and 1.8-
fold increases in H3K9 and H4K5, respectively (Fig. S2A).
FXN mRNA levels in CNS tissues are not signiﬁcantly altered by
prolonged 106, 136 or 109 treatment
To investigate if the increased acetylation that we found in FXN
histone residues was reﬂected by changes of FXN transcription, we
determined FXN mRNA levels in brain and other CNS tissues by
quantitative RT-PCR, comparing HDAC inhibitor-treated and vehicle-
treated YG8R and wild-type samples. Surprisingly, no substantial
increases in FXN expression were detected following any of the three
HDAC inhibitor treatments (Figs. S3 and S4). Some modest increases
of FXN expression were detected, particularly in spinal cord samples,
but none of the changes were statistically signiﬁcant. However, the
relative FXN expression levels in 136- and 109-treated tissues,
compared with vehicle-treated tissues, were consistently higher in
YG8R mice than in WT mice, suggesting some element of speciﬁcity
towards increasing FXN expression in the transgenic FRDA mousemodel (Fig. S3). As our ChIP experiments had also revealed a sig-
niﬁcant effect of 109 on acetylated H3 and H4 histone residues within
the endogenous Gapdh gene, we also assessed brain Gapdh mRNA
expression levels but detected no signiﬁcant changes (Fig. S2B).
109 increases frataxin protein expression in the brain of YG8R FRDA mice
The same brain tissue samples that had been used to determine
FXN expression levels were also used to assess comparative levels of
frataxin protein expression by Western blotting analysis (Fig. 5A).
Modest 1.6-fold and 2-fold increases were seen in 106- and 136-
treated YG8Rmice, respectively, compared with vehicle-treated YG8R
mice. However, 109-treated YG8R mice revealed a much more
signiﬁcant 2.6-fold increase in frataxin expression when compared
with vehicle-treated YG8R mice (pb0.05) (Fig. 5B). 1.3-fold and
1.5-fold increases in endogenous mouse frataxin levels were also
seen in 136- and 109-treated wild-type mice, respectively, suggest-
ing a minor generalized frataxin-increasing effect of these drugs,
although the increases were not statistically signiﬁcant (Fig. 6).
109 increases aconitase enzyme activity within YG8R mouse brain tissue
A consistently observed effect of the frataxin deﬁcit in FRDA
patients, FRDA mouse models and yeast models is a reduction in
activity of the iron–sulfur cluster containing enzyme aconitase
(Bradley et al., 2000; Puccio et al., 2001; Rotig et al., 1997). We have
also previously detected reduced levels of aconitase activity in heart
tissue from our YG8R mice (Al-Mahdawi et al., 2006). Therefore, we
Fig. 5. Frataxin protein levels in YG8R brain tissues. (A) Representative Western blot
showing frataxin protein expression, togetherwithα-tubulin controls, from vehicle (v)-
and 109-treated YG8R mouse brain tissues. (B) Densitometry calculations of frataxin
levels are shown for vehicle-, 106-, 136- and 109-treated YG8R mouse brain samples.
Values are shown relative to the vehicle-treated YG8Rmouse value. In all cases n=4and
error bars represent s.e.m. *pb0.05.
Fig. 7. Aconitase activity of YG8R brain tissues. Aconitase activities for vehicle-treated
wild-type (WT) mice, and vehicle-, 136- and 109-treated YG8R mouse brain samples
are shown as ratios of the corresponding citrate synthase activity and relative to the
vehicle-treated WT mouse value set at 100%. n=3–8 and error bars represent s.e.m.
**pb0.01, ***pb0.001.
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reduced in YG8R brain tissue and whether such activity could be
inﬂuenced by HDAC inhibitor treatment. Our analysis shows that
there is indeed a signiﬁcant reduction in YG8R brain aconitase activity
to 17% of wild-type levels (pb0.001) (Fig. 7). This reduced aconitase
activity was subsequently increased 1.4-fold by treatment with 136.
However, a much more signiﬁcant 4-fold increase occurred with 109
treatment (pb0.001), returning the aconitase activity substantially
towards wild-type levels.
109 ameliorates DRG neuronal pathology
We initially conﬁrmed the presence of vacuolar pathology within
the large neuronal cell bodies of lumbar DRG as a disease phenotype
within the vehicle-treated YG8R mice, as we have previously
described (Al-Mahdawi et al., 2006) (Fig. 8A). Quantiﬁcation of this
vacuolar pathology was then performed by calculating the number ofFig. 6. Frataxin protein levels inwild-typemouse brain tissues. (A)Western blot showing
frataxin protein expression, together withα-tubulin controls, from vehicle (v)-, 109- and
136-treatedwild-typemousebrain tissues. (B)Densitometry calculationsof frataxin levels
are shown for vehicle-, 136- and 109-treatedwild-type (WT)mouse brain samples. Values
are shown relative to the vehicle-treated WT mouse value and increases were not
statistically signiﬁcant. In all cases n=4 and error bars represent s.e.m.vacuole-containing neuronal cells as a percentage of total neuronal
cells within the DRG sections, resulting in a value of 17.5% for YG8R
mice, compared with only 0.9% for wild-typemice. 136 treatment was
found to produce a small reduction in the level of DRG pathology, with
the vacuole count reaching a value of 13.9% (p=0.06) (Fig. 8C).
However, 109 treatment produced a much more signiﬁcant reduction
in DRG pathology (Fig. 8B), with the vacuole count reaching a value of
4.7% (pb0.001) (Fig. 8C), thus indicating substantial amelioration of
the disease-like phenotype.
Discussion
The recent understanding that FRDA disease pathogenesis involves
GAA expansion-induced histone deacetylation of the FXN gene hasFig. 8. DRG neuronal pathology: (A) Representative H&E-stained histology sections of
lumber DRG from (A) vehicle-treated and (B) 109-treated YG8R mice. Vacuolar
pathology of neuronal cell bodies, which is present only in the vehicle-treated section
(A), is indicated by the arrows. Original magniﬁcation=400×. (C) Graphic represen-
tation showing the degree of DRG histopathology in vehicle-treated wild-type (WT)
and vehicle-, 136- and 109-treated YG8R mice, calculated as the percentage of neurons
containing vacuoles compared to the total number of neurons. In all cases n=16 and
error bars represent s.e.m. ***pb0.001.
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(Gottesfeld and Pandolfo, 2009). Initial short-term dosing studies
with the pimelic o-aminobenzamide HDAC inhibitors 106, 109 and
136 have demonstrated efﬁcacy at up-regulating frataxin expression
in FRDA cells and KIKI mouse model tissues, while exhibiting minimal
toxicity (Chou et al., 2008; Herman et al., 2006; Rai et al., 2010, 2008;
Soragni et al., 2008). In this present study, we investigated the chronic
dosing effects of 106, 109 and 136 in our YG8R FRDA mouse model.
We report for the ﬁrst time that prolonged subcutaneous adminis-
trations of 106, 109 and 136 are all well tolerated in mice at the tested
doses, concurring with a recent long-term study of the related HDAC
inhibitor 4b, which demonstrated amelioration of the Huntington
disease phenotype in R6/2 mice without any discernable toxicity
(Thomas et al., 2008). Furthermore, we report treatment-induced
increases of acetylated histones and frataxin expression levels in
YG8R mouse brain, demonstrating that 106, 109 and 136 can each
cross the blood–brain barrier to exert HDAC inhibitory effects, in
agreement with previous short-term KIKI mouse studies (Rai et al.,
2010, 2008).
The HDAC inhibitor treatments did not elicit any dramatic changes
in the behavior deﬁcits of YG8R mice, but modest changes were
moved in the improved direction by drug treatment, including
improved motor coordination with 106 and 109 and increased
locomotor activity with 109 and 136. Such differential behavioral
effects may be due to differences in HDAC inhibitor potency,
speciﬁcity, tissue distribution and effectiveness at crossing the
blood–brain barrier. For example, 109, which elicited improvements
in both behavioral measurements, has been reported to exhibit
selectivity for HDAC3, but retains the most potency for HDAC1 and
HDAC2 among these three pimelic o-aminobenzamide compounds
(Rai et al., 2010).
Our results of the treatment effects on histone acetylation at the
FXN locus by ChIP analysis of brain tissue are in general agreement
with previous studies but substantially extend these studies and, as a
consequence, provide further evidence for the greater potency of 109
compared with 106 or 136. Thus, we have shown that 109 treatment
signiﬁcantly increases acetylation of H4K5 at the FXN upstream GAA
region, while 136 treatment has little effect, as similarly described for
studies of FRDA patient PBMCs and KIKI mouse brain tissues (Rai et al.,
2010). However, we did not detect any 106-induced increase in
acetylation of H4K5 at the FXN upstream GAA region, contrary to the
106 effect reported for the KIKI mouse (Rai et al., 2008). This
discrepancy is most likely due to the different frataxin intron 1
sequences, including gene regulatory sequences, which have been
studied in the two mouse models; the YG8R mouse has human FXN
transgenic sequence, while the KIKI mouse has murine Fxn sequence.
Our study is the ﬁrst study to report any treatment effects of 106, 109
or 136 on the FXN upstream GAA region acetylation status of residues
H3K9 and H4K12; the two histone residues that show the greatest
deacetylation in FRDA disease (Al-Mahdawi et al., 2008; Herman et al.,
2006; Soragni et al., 2008). Signiﬁcant increases in acetylation of H3K9
were identiﬁed only with 109 treatment. In contrast, 106 and 136 had
no effect, as previously described for the related HDAC inhibitor 4b
that similarly did not induce any H3K9 acetylation changes in the
upstream GAA region of human FRDA lymphoblastoid cells but rather
preferentially increase acetylation of H3K14 and H4K5 (Herman et al.,
2006). Our study also detected treatment effects of HDAC inhibitors
on histone acetylation at the FXN promoter and downstream GAA
regions. We identiﬁed modest 106-induced increases in acetylation
of H4K5 in both regions and modest increases in acetylation of
H4K12 in the FXN promoter after treatment with all three com-
pounds. However, the most signiﬁcant changes that we detected
were 109-induced increases in H3K9 and H4K5 acetylation.
Despite the marked 109-induced increases that we detected in
acetylated H3 and H4 residues at the FXN locus in brain tissues of
YG8R mice, we did not ﬁnd any corresponding increase in brain FXNmRNA expression, but we did detect a signiﬁcant 2.6-fold increase in
frataxin protein expression. Differential timings of frataxin mRNA and
protein expression could well account for this apparent discrepancy
or possibly dose levels and dose frequency did not achieve maximal
exposure and efﬁcacy for each compound. Moreover, we cannot rule
out the possibility of 109-induced post-transcriptional effects on
frataxin expression, such as increased frataxin protein stability, as
suggested by our detection of small increases in endogenous mouse
frataxin in HDAC inhibitor-treated wild-type mice as well as the more
signiﬁcant increase of human transgenic frataxin in the 109-treated
YG8R mice. HDAC inhibitors have been shown to change the
transcription of many genes (Drummond et al., 2005; Rai et al.,
2008; Reid et al., 2005; Thomas et al., 2008) and some gene expression
changes may result in enhanced protein stability, as described in one
recent study (Garbes et al., 2009). A similar ﬁnding to ours has also
been reported for the potential FRDA therapeutic compound rhuEPO,
where treatment of primary FRDA ﬁbroblasts produced up to 2-fold
increases in frataxin protein levelswithout any changes in FXNmRNA
expression (Acquaviva et al., 2008). The authors of this study
similarly hypothesized that rhuEPO may stabilize frataxin protein
by an as yet unknown mechanism. More extensive studies will
therefore be necessary to determine the mechanism(s) whereby the
pimelic o-aminobenzamide HDAC inhibitors increase frataxin pro-
tein levels. Interestingly, one recent study has identiﬁed lysine
residue 147 to play a critical role in frataxin ubiquitination and
degradation (Ruﬁni et al., 2011). Therefore, if acetylation of lysine
147 also occurs as a competing post-translational modiﬁcation of
frataxin, or indeed if any of the other 12 frataxin lysine residues prove
to be acetylated, HDAC inhibitors could potentially exert an effect of
promoting frataxin protein stability.
Aconitase is an Fe–S-containing enzyme that exists in both
mitochondrial and cytosolic forms, and a deﬁcit in aconitase activity
has previously been identiﬁed as a major effect of decreased frataxin
in FRDA patients, mouse models and yeast models (Al-Mahdawi et al.,
2006; Bradley et al., 2000; Puccio et al., 2001; Rotig et al., 1997). Thus,
aconitase activity can be considered a suitable biomarker of FRDA
disease. The substantial deﬁcit of aconitase activity that we identiﬁed
in the brain tissue of our YG8R mouse (14% of wild-type) is similar to
deﬁcits that have been reported for human tissues (Bradley et al.,
2000), but perhaps more substantial than may have been expected
considering the comparatively mild degree of brain frataxin protein
reduction in this mouse model (70% of wild-type) (Al-Mahdawi et al.,
2006). However, it is very likely that the transgenic human frataxin
protein produced within the YG8R mouse will not function as ef-
fectively as endogenous mouse frataxin protein due to amino acid
sequence differences, thereby compounding the frataxin deﬁcit and
hence the aconitase deﬁcit. Most interestingly, after treatment with
HDAC inhibitors, the best improvement in aconitase activity was
found to be with 109, the HDAC inhibitor that produced the most
signiﬁcant changes in histone acetylation, together with the largest
subsequent increases in frataxin expression.
Degeneration of the large sensory neurons within the DRG has
long been known as a prominent feature of FRDA disease (Koeppen
et al., 2009), and more recently the formation of pathological vacuoles
within these particular cells has also been reported in several FRDA
mouse models (Al-Mahdawi et al., 2006; Puccio et al., 2001; Simon
et al., 2004). Using the occurrence of DRG vacuoles as a marker of
FRDA disease pathology in our YG8R mice, we have shown that, as
with restoration of the aconitase deﬁcit, the HDAC inhibitor that
produced the most signiﬁcant improvement in DRG neuronal cell
pathology is 109, the HDAC inhibitor that produced the most
signiﬁcant increase in frataxin expression. This suggests that 109
may be exerting beneﬁcial effects on both aconitase activity and
neuronal pathology as a direct consequence of its ability to increase
frataxin protein expression. However, it is also possible that some of
the amelioration of neuronal pathology is due to an additional more
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the effect of HDAC inhibitor 4b on the R6/2 HDmousemodel (Thomas
et al., 2008). Therefore, future microarray gene expression analysis of
109-treated mouse tissue would be useful to determine potential
upregulation of neuroprotective genes by 109 treatment.
Conclusions
We have shown that prolonged treatment with each of the three
HDAC inhibitors, 106, 136 and 109 can ameliorate FRDA disease-like
effects to some extent, and therefore our studies are supportive of
advancing HDAC inhibitors for treating FRDA. Furthermore, 109
clearly emerges as a lead drug candidate due to its ability to increase
brain frataxin protein and aconitase activity and reduce DRG neuronal
pathology in our FRDA mouse model. These beneﬁcial effects are also
likely to account for the modest improvements in motor coordination
performance and locomotor activity that we observed with 109 treat-
ment. However, the behavioral deﬁcits of the YG8R mouse model are
still rather mild, and therefore, by exploiting the unstable nature of
the GAA repeat mutation, we are currently developing a larger GAA
repeat-based FRDA mouse model with more substantial reduction in
FXN expression and a more severe behavioral phenotype that would
be beneﬁcial to future drug testing. It may also be useful to investigate
the more global effects of prolonged 109 treatment by performing
microarray gene expression proﬁling of treated YG8R mice, in a
similar manner to studies of the related HDAC inhibitors 4b and 106
that have each identiﬁed expression changes in only a limited number
of genes (Rai et al., 2008; Thomas et al., 2008). Several HDAC inhib-
itors have now been evaluated for the treatment of a variety of genetic
disorders, such as spinal muscular atrophy (SMA) (Garbes et al., 2009;
Hahnen et al., 2006; Kernochan et al., 2005; Riessland et al., 2006),
Huntington disease (Butler and Bates, 2006; Hockly et al., 2003;
Thomas et al., 2008), cardiac hypertrophy (Antos et al., 2003) and
cystic ﬁbrosis (Hutt et al., 2010). To add to this list, we have now
shown that the pimelic o-aminobenzamide compound 109 is safe and
effective at up-regulating frataxin expression in prolonged treatment
of an FRDAmouse model. These studies support continued evaluation
of HDAC inhibitors to treat Friedreich ataxia.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.nbd.2011.02.016.
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